List of Excipients in Branded Drug INDIUM IN 111 OXYQUINOLINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medi-Physics Inc dba GE Healthcare	INDIUM IN 111 OXYQUINOLINE	indium in-111 oxyquinoline	17156-021	POLYSORBATE 80

Generic Drugs Containing INDIUM IN 111 OXYQUINOLINE

Company	Ingredient	NDC	Excipient
BWXT Medical Ltd	indium in-111 oxyquinoline	72536-0920	HYDROCHLORIC ACID
BWXT Medical Ltd	indium in-111 oxyquinoline	72536-0920	HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID
BWXT Medical Ltd	indium in-111 oxyquinoline	72536-0920	POLYSORBATE 80

What are the Most Frequently-Used Excipients in INDIUM IN 111 OXYQUINOLINE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID
1	POLYSORBATE 80

Indium In-111 Oxyquinoline Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Indium In-111 oxyquinoline is an established diagnostic radiopharmaceutical used primarily to label autologous leukocytes for imaging suspected infection and inflammation. Its commercial opportunity is not based on a new active ingredient patent. It is based on reliable radiochemical performance, leukocyte viability, short supply-chain windows, kit simplification, automated preparation, geographic availability, and compliance with radiopharmaceutical manufacturing standards.

The strongest product strategy is a ready-to-use or near-ready-to-use sterile formulation with controlled pH, low metal contamination, validated radiochemical purity, and packaging that minimizes adsorption and operator exposure.

What is Indium In-111 oxyquinoline used for?

Indium In-111 oxyquinoline is used to radiolabel a patient’s white blood cells ex vivo. The labeled leukocytes are reinjected and imaged by planar scintigraphy or SPECT to identify sites of infection or inflammation.

Indium-111 has a physical half-life of approximately 67.3 hours and emits principal gamma photons at about 171 and 245 keV. Oxyquinoline acts as a lipophilic carrier that facilitates cellular entry of indium. Inside the leukocyte, indium becomes associated with intracellular components, supporting retention during imaging.[1]

The principal clinical application is localization of occult infection, including suspected abdominal, skeletal, pulmonary, vascular graft, prosthetic joint, and soft-tissue infection. Use depends on institutional expertise and is generally reserved for cases in which anatomic imaging or other nuclear medicine studies do not provide a sufficient answer.

What dosage form and route are used?

The product is supplied as a sterile injectable solution for in vitro radiolabeling of autologous leukocytes. It is not normally administered directly to the patient as free oxyquinoline or as an unlabeled indium compound.

The labeling workflow typically includes:

1. Collection of autologous leukocytes.
2. Incubation with Indium In-111 oxyquinoline.
3. Washing and removal of unbound radiolabel.
4. Quality-control testing.
5. Reinjection into the same patient.
6. Delayed imaging after cellular distribution.

This workflow creates a commercial distinction between the drug product and the labeling service. A formulation that reduces incubation time, improves recovery, or simplifies quality control can create more value than a small change in excipient composition.

Which excipients are relevant to Indium In-111 oxyquinoline?

Public product information identifies an aqueous sterile formulation containing the radiolabeled indium-oxyquinoline complex and conventional pharmaceutical excipients used to control pH, tonicity, and chemical stability. Commercial presentations may differ by manufacturer and market.

Relevant excipient classes include:

Excipient or material class	Function	Primary development concern
Hydrochloric acid	Controls acidic preparation conditions and supports indium chloride chemistry	Excess acidity can reduce leukocyte compatibility after transfer
Sodium hydroxide	pH adjustment	Local concentration and precipitation risk
Sodium chloride	Tonicity and ionic-strength control	Osmolality after addition to the cell-labeling system
Water for injection	Sterile vehicle	Endotoxin, particulate, and metal-control requirements
Oxyquinoline	Chelating and cell-entry ligand; technically the key non-radioactive component	Purity, concentration, cellular toxicity, and radiochemical yield
Container and closure materials	Protect the product and control adsorption	Extractables, leachables, radiolabel binding, and radiation exposure

Oxyquinoline is often described as the chelating ligand rather than as an inactive excipient. From a formulation and regulatory standpoint, its role is active in the radiolabeling process even though the final clinical procedure uses labeled cells.

What excipient attributes control product performance?

The most important attributes are:

• pH and buffer capacity;
• trace-metal content;
• oxyquinoline concentration;
• radiochemical purity;
• free indium content;
• chemical purity of oxyquinoline;
• endotoxin and sterility;
• osmolality after dilution or cell exposure;
• compatibility with plastic syringes, vials, tubing, and cell-separation equipment;
• stability during radioactive decay and shipment.

Trace metals are a particular concern. Competing metals can bind oxyquinoline or indium, reduce labeling efficiency, and increase the fraction of unbound radiometal. Excipient raw materials therefore require tighter elemental-impurity controls than a conventional low-risk injectable may require.

How should an excipient strategy be designed?

The preferred strategy is a minimalist, low-metal, low-buffer formulation that is compatible with leukocytes and does not require extensive manipulation by radiopharmacy staff.

Strategy 1: Optimize the current aqueous formulation

A conventional aqueous formulation has the lowest regulatory and operational burden. Development should focus on:

• tighter control of pH;
• reduction of trace-metal impurities;
• improved vial adsorption performance;
• validated stability through the usable radioactive window;
• protection from light where needed;
• reduced residual free indium;
• compatibility with automated cell-labeling systems.

This route is commercially attractive because it can improve reliability without changing the clinical procedure.

Strategy 2: Develop a single-use labeling kit

A kit could contain the non-radioactive oxyquinoline component, sterile transfer materials, labeling instructions, and quality-control supplies. The radioactive indium component could be added shortly before use by an authorized radiopharmacy.

The principal benefit is operational standardization. A kit can reduce preparation variability across hospitals and support decentralized use where a fully manufactured radioactive product is difficult to distribute.

The principal regulatory issue is the division between kit components. If the kit is marketed as a drug product, the sponsor must establish the performance of the assembled system. If it is sold as a device or accessory, the claims must avoid implying that it independently performs the radiolabeling function without the applicable drug authorization.

Strategy 3: Develop a ready-to-use syringe or vial

A ready-to-use presentation could reduce preparation steps, radiation exposure, and operator time. The main constraints are radioactive decay, shipping schedules, dose calibration, and the short practical shelf life.

A commercial product could be supplied in a patient-specific syringe, a calibrated multidose vial, or a small-volume single-dose vial. The syringe format may improve dose administration but creates greater risks of adsorption, dead volume, and compatibility problems.

Strategy 4: Use excipient and container systems to improve automation

An excipient package can be designed around automated leukocyte labeling platforms. The relevant commercial claims would concern:

• consistent labeling yield;
• reduced incubation time;
• improved cell recovery;
• reduced manual transfers;
• compatibility with closed or semi-closed systems;
• lower residual free indium;
• validated performance across leukocyte concentrations.

This opportunity is more defensible than a generic claim to an old indium-oxyquinoline composition. Patent protection could focus on a defined formulation combined with a labeling method, container system, or automated workflow.

What formulation patents could protect Indium In-111 oxyquinoline?

The original active-ingredient and labeling technology is old. Broad composition claims covering indium-111 oxyquinoline or the general use of labeled leukocytes are unlikely to provide meaningful new exclusivity in major markets.

Potentially protectable subject matter includes:

Potential claim area	Commercial value	Patent vulnerability
Low-metal oxyquinoline formulation	Medium	Prior-art and obviousness risk
Defined pH and osmolality range	Low to medium	May be treated as routine optimization
Stabilized sterile solution	Medium	Requires demonstrated stability or performance benefit
Low-adsorption container system	Medium	Stronger if linked to measurable dose recovery
Shortened leukocyte-labeling process	High	Requires reproducible technical improvement
Automated closed-system labeling kit	High	More differentiated than composition alone
Improved cell recovery or viability	High	Requires comparative clinical or laboratory data
Point-of-care or decentralized kit	Medium to high	Regulatory classification must be carefully structured
Method of imaging infection with labeled leukocytes	Low	Broad claims face prior-art limitations
Manufacturing process for high-purity oxyquinoline	Medium	Value depends on supply-chain advantage

A new patent should avoid relying only on narrow concentration ranges unless the range produces a demonstrated effect. Stronger protection would link composition parameters to measurable outcomes such as radiochemical yield, cell viability, retained intracellular activity, dose recovery, or reduced operator exposure.

When does Indium In-111 oxyquinoline lose exclusivity?

The product is an old radiopharmaceutical with no meaningful remaining period of new chemical entity exclusivity. Any original composition or method patents would have expired or be close to expiration, depending on the jurisdiction and the particular patent family.

The commercial exclusivity analysis is therefore different from a modern small-molecule launch:

Exclusivity category	Current commercial significance
New chemical entity exclusivity	No practical remaining protection
Original composition patents	Generally expired or commercially obsolete
Formulation patents	Product-specific and potentially available only for new improvements
Method-of-use patents	Narrow opportunity; depends on a new approved indication
Orphan-drug exclusivity	Not generally associated with the established product
Pediatric exclusivity	No known central role
Regulatory data exclusivity	Not a meaningful barrier for this established product
Trade secrets	Relevant for sterile manufacture, quality control, and logistics
Supply agreements	Potentially more important than patents

The principal barrier to competition is execution. Radiopharmaceutical supply requires licensed facilities, radioactive-material handling, validated sterility systems, dose calibration, qualified transport, and rapid distribution. These requirements can protect revenue even when patent protection is weak.

What is the FDA regulatory status and Orange Book position?

Indium In-111 oxyquinoline is an FDA-approved diagnostic radiopharmaceutical product used for leukocyte labeling. FDA labeling describes the product as a sterile solution for in vitro labeling of autologous leukocytes and includes handling, preparation, radiation-safety, and administration requirements.[2]

The product is regulated as a drug and radiopharmaceutical. Manufacturing must comply with applicable drug-current-good-manufacturing-practice requirements and radiopharmaceutical-specific controls. FDA regulations governing PET drugs are not the complete regulatory framework for a non-PET radiopharmaceutical such as Indium In-111 oxyquinoline.[3]

The Orange Book is relevant for approved drug products and listed patent information, but this product category generally does not have the dense patent-listing profile associated with high-revenue oral medicines. The absence of an active listed patent would materially reduce the relevance of a Paragraph IV strategy.

Are there Paragraph IV challenges or generic-entry cases?

A conventional Paragraph IV strategy has limited commercial relevance unless an active Orange Book-listed patent covers the reference product. For an old radiopharmaceutical, competition is more likely to arise through:

• an abbreviated or streamlined application pathway, where available;
• a competing full drug application;
• a contract-manufactured product;
• a hospital or radiopharmacy preparation model;
• a new kit or labeling platform;
• regional products manufactured under local radiopharmaceutical rules.

Publicly visible market activity is more likely to involve product availability, manufacturing authorization, or supply arrangements than high-profile Hatch-Waxman litigation.

A competitor could still challenge a formulation patent if one were listed. The economic value of the challenge would depend on hospital purchasing behavior, annual procedure volume, product concentration, and whether the reference sponsor has reliable supply. Patent litigation would be less attractive if the market is fragmented and the product has low unit revenue.

What patent litigation and settlement agreements affect the product?

No major current litigation or widely reported settlement agreement is central to the commercial position of established Indium In-111 oxyquinoline products. The more material legal risks concern:

• manufacturing authorization;
• radiopharmacy licensing;
• chain-of-custody requirements;
• sterile-process validation;
• contract manufacturing;
• trademark and labeling rights;
• import and export controls for radioactive material;
• patent claims directed to new kits, containers, or automated labeling methods.

A new entrant should conduct a freedom-to-operate review covering indium chelation, leukocyte labeling, automated cell processing, closed-system transfer devices, and container technologies. The highest risk may arise outside the narrow drug composition.

How strong is the patent estate for Indium In-111 oxyquinoline?

The legacy patent estate is weak as a basis for exclusivity. The product’s defensibility is better described as operational and regulatory than patent-based.

Estate component	Assessment
Active-ingredient protection	Weak
Broad formulation protection	Weak for legacy products
New formulation opportunities	Moderate if linked to performance data
Method-of-use protection	Narrow
Manufacturing know-how	Moderate
Sterility and radiopharmaceutical quality systems	Moderate to strong operational barrier
Distribution and isotope access	Moderate to strong
Automated labeling platform patents	Potentially strong, depending on claims
Brand and institutional relationships	Commercially important

The most valuable intellectual property may cover process control, closed-system labeling, dose recovery, software-controlled preparation, and validated integration with cell-separation systems.

What commercial opportunities exist for excipient suppliers and manufacturers?

The addressable opportunity is specialized rather than mass-market. Attractive areas include:

Low-metal excipient supply

Suppliers can offer pharmaceutical-grade oxyquinoline and excipient materials with documented elemental-impurity profiles. Certificates should address metals that compete with indium or affect radiochemical performance.

Radiopharmacy-ready kits

A kit that standardizes leukocyte labeling can reduce staff time and procedural variation. The kit may include sterile vessels, transfer devices, validated incubation containers, and quality-control consumables.

Container-closure systems

Low-binding vials, syringes, and tubing can improve dose recovery. This is a practical development area because radioactive dose loss can directly affect product economics and imaging quality.

Automated labeling

Automation can reduce operator exposure and improve reproducibility. A manufacturer that combines the drug product with a validated labeling workflow may gain a stronger commercial position than a supplier selling the same active formulation.

Regional manufacturing hubs

Because Indium-111 has a 67.3-hour half-life, centralized national distribution is feasible in some markets but not all. Regional fill-finish and radiopharmacy networks can reduce decay losses and improve delivery reliability.

Competing diagnostic modalities

The market competes with technetium-99m-labeled leukocyte procedures, fluorodeoxyglucose PET, gallium-67 imaging, and anatomic imaging. A commercial product must demonstrate workflow or diagnostic advantages, not merely chemical equivalence.

How does Indium In-111 oxyquinoline compare with alternative infection-imaging products?

Product or modality	Main advantage	Main limitation
Indium In-111 oxyquinoline-labeled leukocytes	Direct imaging of leukocyte accumulation; established method	Labor-intensive ex vivo labeling and delayed imaging
Tc-99m HMPAO-labeled leukocytes	Lower radiation burden and more favorable imaging logistics	Different labeling workflow and shorter radionuclide half-life
FDG PET/CT	High sensitivity and broad availability in many centers	Inflammation and infection may be difficult to distinguish; not cell-specific
Gallium-67 citrate	Established inflammatory imaging	Longer imaging schedule and lower resolution
CT or MRI	Strong anatomic detail	May not identify active infection reliably in all settings
Radiolabeled monoclonal antibodies or peptides	Potentially targeted imaging	More complex development and regulatory requirements

Indium In-111 oxyquinoline remains commercially relevant where direct leukocyte localization is clinically preferred and the institution has the necessary radiopharmacy infrastructure.

What revenue exposure and generic-launch risks exist?

Revenue exposure depends on procedure volume, reimbursement, hospital purchasing, and supply reliability. The product is unlikely to generate the revenue profile of a mass-market chronic medicine. Its value is concentrated in nuclear medicine departments, specialty hospitals, infection-imaging centers, and radiopharmacy networks.

Generic-launch risk is moderate operationally but low in the classic patent sense. A competitor can enter if it can reproduce:

• sterile manufacture;
• radiochemical quality;
• leukocyte compatibility;
• dose calibration;
• shelf-life performance;
• radioactive shipping;
• hospital supply continuity;
• validated labeling instructions.

A launch scenario based only on a lower price may have limited impact if the market is supply constrained. A competitor offering better availability, simpler preparation, automated compatibility, or lower operator exposure could gain share without owning a stronger patent estate.

Key Takeaways

• Indium In-111 oxyquinoline is an established diagnostic radiopharmaceutical for ex vivo labeling of autologous leukocytes.
• The product’s commercial value depends more on radiopharmacy execution than on remaining legacy patent exclusivity.
• The most relevant excipient controls are pH, trace metals, oxyquinoline purity, osmolality, radiochemical purity, and container compatibility.
• A ready-to-use syringe, single-use kit, or automated closed-system workflow offers greater commercial differentiation than a conventional composition patent.
• Broad active-ingredient patents are unlikely to provide meaningful current protection.
• Formulation patents can be pursued only where defined excipient parameters produce measurable gains in labeling yield, cell viability, dose recovery, or stability.
• Paragraph IV litigation is less likely to drive market entry than competing full applications, radiopharmacy manufacturing, regional supply, and device-integrated workflows.
• The strongest defensible position combines sterile manufacturing, radioactive-material logistics, validated labeling performance, and institutional supply contracts.

FAQs

Can oxyquinoline concentration be changed without a new regulatory submission?

A concentration change can affect radiochemical purity, leukocyte viability, labeling yield, and patient-use instructions. It would require regulatory assessment and supporting comparability data.

Is Indium In-111 oxyquinoline eligible for biosimilar competition?

No. It is a radiolabeled small-molecule diagnostic product, not a biological product. Biosimilar pathways do not apply.

Can a hospital compound Indium In-111 oxyquinoline independently?

Radiopharmaceutical preparation is subject to applicable FDA, state, pharmacy, radioactive-material, sterility, and institutional requirements. Hospital preparation does not eliminate the need for validated procedures and quality controls.

What is the strongest patent claim for a new product?

A claim linking a defined low-metal formulation to improved leukocyte labeling, retained intracellular activity, cell viability, or automated closed-system processing is generally more commercially meaningful than a narrow excipient concentration claim alone.

Which commercial model is most attractive?

A regional radiopharmacy model combined with a standardized labeling kit or automated workflow is more attractive than selling an undifferentiated aqueous vial. It addresses supply reliability, labor, radiation exposure, and preparation variability.

References

1. International Atomic Energy Agency. (2015). Radioisotopes and radiopharmaceuticals in medicine: Indium-111 physical and clinical characteristics. IAEA.

2. U.S. Food and Drug Administration. (n.d.). Indium In-111 oxyquinoline injection: Prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2024). Radiopharmaceutical drugs: Current good manufacturing practice and regulatory requirements. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

5. United States Pharmacopeia. (2024). Indium In-111 oxyquinoline injection. In United States Pharmacopeia and National Formulary. USP.